388082-75-5

Basic information

• Product Name: 2-Furancarboxaldehyde,5-[4-[[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]aMino]-6-quinazolinyl]-, Mono(4-Methylbenzenesulfonate)
• Synonyms: 2-Furancarboxaldehyde,5-[4-[[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]aMino]-6-quinazolinyl]-, Mono(4-Methylbenzenesulfonate);5-[4-[[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furancarbaldehyde tosylate
• CAS NO: 388082-75-5
• Molecular Formula: C33H25ClFN3O6S
• Molecular Weight: 646
• Mol File: 388082-75-5.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Furancarboxaldehyde,5-[4-[[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]aMino]-6-quinazolinyl]-, Mono(4-Methylbenzenesulfonate)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Furancarboxaldehyde,5-[4-[[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]aMino]-6-quinazolinyl]-, Mono(4-Methylbenzenesulfonate)(388082-75-5)
• EPA Substance Registry System: 2-Furancarboxaldehyde,5-[4-[[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]aMino]-6-quinazolinyl]-, Mono(4-Methylbenzenesulfonate)(388082-75-5)

Safety Data

• Hazardous Substances Data: 388082-75-5(Hazardous Substances Data)

Upstream product

• 231278-20-9 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine 
• 13529-27-6 2-(diethoxymethyl)furan 
• 104-15-4 toluene-4-sulfonic acid 
• 202197-25-9 {4-[(3-fluorobenzyl)oxy]phenyl}amine 
• 27329-70-0 5-formylfurane-2-boronic acid 
• 202197-26-0 3-chloro-4-(3-fluorobenzyloxy)aniline 
• 98556-31-1 4-chloro-6-iodoquinazoline 
• 16064-08-7 6-iodoquinazolin-4(3H)-one 
• 98-01-1 furfural 
• 7647-10-1 palladium(II) chloride 
• 231278-84-5 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde 

Relevant articles and documents

SALTS OF LAPATINIB

The present invention provides novel dioxalate salt of lapatinib, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides novel monobesylate salt of lapatinib, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides a process for the preparation of monohydrate form of lapatinib ditosylate. The present invention further provides a process for the preparation of anhydrous form of lapatinib ditosylate.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional EGFR and/or erbB-2 inhibitor. In particular, the method relates to methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional EGFR and/or erbB-2 inhibitor.